ORCID

Abstract

ABSTRACTBackground: Psychotropics (sometimes off-label), mental health diagnoses and behaviours of concern are common in olderadults with intellectual disability. Guidelines recommend non-pharmacological interventions and regular medication review.This study examined changes in psychotropics among older adults (≥40) with intellectual disability.Methods: Longitudinal data were obtained from the Intellectual Disability Supplement to the Irish Longitudinal Study onAgeing (IDS-TILDA) at two timepoints [Wave 1(2009/10); Wave 4(2019/20)]. Post hoc analysis, Chi-squared tests and univariatebinary logistic regression were conducted.Results: Overall, psychotropics decreased (59.2% to 56.5%). Significant decreases in antipsychotics (43.1%–40.1%) and sedatives/hypnotics (13.6%–8.1%) and significant increase in antidepressants (26.2%–31.8%) were found. Nearly half of antidepressant usersreported depression at Wave 1, compared with under 30% at Wave 4. Antipsychotics and antidepressants were common (75% and60%, respectively) among those with behaviours of concern, after excluding clinical indications.Conclusion: Psychotropic prescribing remained consistent, though class-specific patterns shifted, with some decreases or increases observed.

Publication Date

2026-01-29

Publication Title

Journal of Applied Research in Intellectual Disabilities

Volume

39

Issue

1

ISSN

1360-2322

Acceptance Date

2025-12-17

Deposit Date

2026-01-31

Funding

R.S. has received institutional and research support from LivaNova, UCB, Eisai, Veriton Pharma, Bial, Angelini, UnEEG and Jazz/GW pharma outside the submitted work. He holds grants from NIHR AI, SBRI and other funding bodies, all outside this work. No other authors have conflicts of interest. This EQUIP study is funded by the Health Research Board (HRB) Secondary Data Analysis Award (SDAP‐2021‐016). IDS‐TILDA is funded by the Health Research Board and the Department of Health (IDS‐TILDA‐2018‐1).

Keywords

antidepressants, antipsychotics, intellectual disability, mental health conditions, psychotropic medicines

Share

COinS